Category - Developments

The HydRx Farms subsidiary of Scientus Pharma has received its Access to Cannabis for Medical Purposes Regulations (ACMPR) license from Health Canada. Scientus now is permitted to begin cultivating medicinal cannabis at...

Arbutus Biopharma’s (NASDAQ:ABUS) lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals (NASDAQ:ALNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for...

MaRS Innovation and Evotec AG (FSE:EVT) have launched LAB150, a Toronto-based partnership to tap infrastructure and drug discovery expertise of Evotec and drug discovery projects from the 15-member institutions of MaRS...

Microbix Biosystems (TSX:MBX) has made its first full-scale shipment of antigen, produced using its new bioreactor manufacturing process, following customer validation. Bioreactors offer the prospect for better process...

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx’s and Par Pharmaceutical’s...

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) announced that the board has formed a committee to identify a new chairman with relevant global experience to guide the company through the anticipated upcoming international...

The CBS affiliate in Boston, WBZ-TV, has aired a segment about the opioid crisis, featuring Probuphine, a six-month implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) that releases a steady dose of buprenorphine...

Shares of Opiant Pharmaceuticals were approved for listing on the Nasdaq Capital Market at the opening tomorrow (August 29) under the symbol, OPNT.  The company’s common stock had traded on the OTCQB Marketplace since...

An article on Fortune magazine’s web site discusses Titan Pharmaceuticals (NASDAQ:TTNP) and its newest implant with a commonly used Parkinson’s disease drug called ropinirole. Last week, the FDA gave Titan the green...

The FDA has cleared an IND application by Titan Pharmaceuticals (NASDAQ:TTNP) for its ropinirole implant intended to treat the signs and symptoms of Parkinson’s disease. A Phase 1/2 clinical study in patients will...